Here’s what you should know: 1. The approval provides increased reimbursement in the outpatient setting. The pass-through program will become effective Jan. 1, 2019. 2. The remede system is an ...
A new device to treat central sleep apnea recently made its debut at UCHealth Medical Center of the Rockies in Loveland. In a recent breakthrough procedure, a man became the first patient in an ...
MINNETONKA, Minn., July 10, 2019 /PRNewswire/ -- Respicardia, Inc., the manufacturer of the only FDA-approved active implantable device for the treatment of central sleep apnea (CSA), today announced ...
The FDA approved an implantable device, Respicardia’s Remede System, which helps fight moderate to severe cases of central sleep apnea, a condition where the brain doesn’t send proper signals to the ...
MINNETONKA, Minn., Respicardia, Inc., a medical technology company developing innovative therapies that improve cardiovascular health, today announced that the Centers for Medicare and Medicaid ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results